我们的分析旨在描述急诊就诊 (EP) 和门诊 (OP) 期间胰腺癌诊断的人口统计特征和差异，并了解我们机构的胰腺多学科诊所 (PMDC) 对这些差异的影响。机构审查委员会-批准对我们的机构癌症登记处和 PMDC 数据库进行回顾性审查，确定了 2014 年至 2022 年间诊断/治疗胰腺导管腺癌的患者。卡方检验用于分类变量，单向方差分析和 Bonferroni 校正用于连续变量。统计显着性设定为 p < 0.05。共有 286 名患者符合纳入标准。 89 名患者 (31.1%) 为代表性不足的少数族裔 (URM)。 EP 期间提出了 57 个 (64.0%) URM，而非 URM 为 100 个 (50.8%) (p = 0.037)。 PMDC 审查了 41 个 (46.1%) URM，而非 URM 则为 71 个 (36.0%) (p = 0.10)。队列之间的临床和病理分期没有差异（p = 0.28）。与非 URM 相比，EP 队列中 URM 接受治疗的时间平均长 22 天（66.5 天 vs. 44.8 天，p = 0.003），OP 队列平均长 18 天（58.0 天 vs. 40.5 天，p < 0.001） 。 EP 队列中的胰腺多学科诊所入组消除了队列之间治疗时间的差异（48.3 天与 37.0 天；p = 0.151）。与非 URM 相比，代表性不足的少数群体更有可能通过 EP 进行诊断，并且治疗时间延迟同行。我们的 PMDC 缓解了其中一些观察到的差异。未来的研究需要阐明导致这些发现的具体因素并确定解决方案。© 2024。作者。

Our analysis was designed to characterize the demographics and disparities between the diagnosis of pancreas cancer during emergency presentation (EP) and the outpatient setting (OP) and to see the impact of our institutions pancreatic multidisciplinary clinic (PMDC) on these disparities.Institutional review board-approved retrospective review of our institutional cancer registry and PMDC databases identified patients diagnosed/treated for pancreatic ductal adenocarcinoma between 2014 and 2022. Chi-square tests were used for categorical variables, and one-way ANOVA with a Bonferroni correction was used for continuous variables. Statistical significance was set at p < 0.05.A total of 286 patients met inclusion criteria. Eighty-nine patients (31.1%) were underrepresented minorities (URM). Fifty-seven (64.0%) URMs presented during an EP versus 100 (50.8%) non-URMs (p = 0.037). Forty-one (46.1%) URMs were reviewed at PMDC versus 71 (36.0%) non-URMs (p = 0.10). No differences in clinical and pathologic stage between the cohorts (p = 0.28) were present. URMs took 22 days longer on average to receive treatment (66.5 days vs. 44.8 days, p = 0.003) in the EP cohort and 18 days longer in OP cohort (58.0 days vs. 40.5 days, p < 0.001) compared with non-URMs. Pancreatic Multidisciplinary Clinic enrollment in EP cohort eliminated the difference in time to treatment between cohorts (48.3 days vs. 37.0 days; p = 0.151).Underrepresented minorities were more likely to be diagnosed via EP and showed delayed times to treatment compared with non-URM counterparts. Our PMDC alleviated some of these observed disparities. Future studies are required to elucidate the specific factors that resulted in these findings and to identify solutions.© 2024. The Author(s).